Management of Menopausal Hot Flashes

Efficacy of Venlafaxine

Venlafaxine is effective for managing menopausal hot flashes, with studies showing a 37-61% reduction in hot flash frequency and severity compared to placebo, as recommended by the American College of Obstetricians and Gynecologists 1
A placebo-controlled trial in breast cancer survivors demonstrated that venlafaxine significantly reduced hot flash scores after 4 weeks, with a 37% reduction at 37.5 mg/day and a 61% reduction at 75 mg/day and 150 mg/day, compared to only 27% reduction with placebo 1
Long-term studies show sustained benefits, with a 12-week study reporting significant improvement in daily living related to hot flash reduction 1
The optimal dose of venlafaxine appears to be 75 mg/day, balancing efficacy and side effects, according to the National Comprehensive Cancer Network 1

Venlafaxine has been directly compared with clonidine in breast cancer survivors, showing faster effect but less well tolerated than clonidine, as reported by the National Comprehensive Cancer Network 2
In a crossover study comparing venlafaxine with gabapentin, both treatments resulted in similar reductions in hot flash severity, but 68% of participants preferred venlafaxine, according to the National Comprehensive Cancer Network 2
Acupuncture has been compared with venlafaxine and found to be equivalent or better in some studies, as reported by the National Comprehensive Cancer Network 2

Common side effects of venlafaxine include dry mouth, decreased appetite, nausea, constipation, and are dose-related and generally mild to moderate, as reported by the American College of Obstetricians and Gynecologists 1
Approximately 10-20% of individuals withdraw from treatment due to adverse events, but this is less likely with lower doses, according to the American College of Obstetricians and Gynecologists 1

Venlafaxine is a first-line non-hormonal option for women who cannot or choose not to use hormone therapy, have a history of breast cancer, or experience moderate to severe hot flashes affecting quality of life, as recommended by the American College of Obstetricians and Gynecologists 1
Treatment typically begins at lower doses (37.5 mg) and can be titrated up based on response, with evaluation of response after 4 weeks of treatment, according to the National Comprehensive Cancer Network 1
If discontinuing, taper gradually to prevent discontinuation symptoms, as recommended by the American College of Obstetricians and Gynecologists 1